Cited by 1,487Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsCancer Risks and Factors

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Open access

Colditz, Graham A., Hankinson, Susan E., Hunter, David J., Willett, Walter C., Manson, JoAnn E., Stampfer, Meir J., Hennekens, Charles, Rosner, Bernard, Speizer, Frank E.·1995·New England Journal of Medicine

DOI 10.1056/nejm199506153322401

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is controversial. METHODS: To quantify the relation between the use of hormones and the risk of breast cancer in postmenopausal women, we extended our follow-up of the participants in the Nurses' Health Study to 1992. The women were asked to complete questionnaires every two years to update information on their menopausal status, use of estrogen and progestin preparations, and any diagnosis of breast cancer. During 725,550 person-years of follow-up, we documented 1935 cases of newly diagnosed invasive breast cancer. RESULTS: The risk of breast cancer was significantly increased among women who were currently using estrogen alone (relative risk, 1.32; 95 percent confidence interval, 1.14 to 1.54) or estrogen plus progestin (relative risk, 1.41; 95 percent confidence interval, 1.15 to 1.74), as compared with postmenopausal women who had never used hormones. Women currently taking hormones who had used such therapy for 5 to 9 years had an adjusted relative risk of breast cancer of 1.46 (95 percent confidence interval, 1.22 to 1.74), as did those currently using hormones who had done so for a total of 10 or more years (relative risk, 1.46; 95 percent confidence interval, 1.20 to 1.76). The increased risk of breast cancer associated with five or more years of postmenopausal hormone therapy was greater among older women (relative risk for women 60 to 64 years old, 1.71; 95 percent confidence interval, 1.34 to 2.18). The relative risk of death due to breast cancer was 1.45 (95 percent confidence interval, 1.01 to 2.09) among women who had taken estrogen for five or more years. CONCLUSIONS: The addition of progestins to estrogen therapy does not reduce the risk of breast cancer among postmenopausal women. The substantial increase in the risk of breast cancer among older women who take hormones suggests that the trade-offs between risks and benefits should be carefully assessed.

Integrity signals

Registry

Crossref · 10.1056/nejm199506153322401

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Variations in mortality by weight among 750,000 men and women
Lew, E. A., & Garfinkel, L. (1979) · Journal of Chronic Diseases · doi:10.1016/0021-9681(79)90119-x · Cited by 1,169
Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk
Pike, M. C., SPICER, D. V., Dahmoush, L., & Press, M. F. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036102 · Cited by 1,009
TEST OF THE NATIONAL DEATH INDEX
Stampfer, M. J., Willett, W. C., Speizer, F. E., DYSERT, D. C., LIPNICK, R. J., ROSNER, B. A., & Hennekens, C. H. (1984) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113804 · Cited by 791
The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer
Key, T. J., & Pike, M. C. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90173-3 · Cited by 658
The Risk of Breast Cancer after Estrogen and Estrogen–Progestin Replacement
Bergkvist, L., Adami, H., Persson, I. R., Hoover, R. N., & Schairer, C. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908033210505 · Cited by 612
The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women
Felson, D. T., Zhang, Y., Hannan, M. T., Kiel, D. P., Wilson, P. W. F., & Anderson, J. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310143291601 · Cited by 580
THE EPIDEMIOLOGY OF SERUM SEX HORMONES IN POSTMENOPAUSAL WOMEN
Cauley, J. A., Gutai, J. P., Kuller, L. H., LEDONNE, D., & POWELL, J. G. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115234 · Cited by 485
Biologic Effects of Transdermal Estradiol
Chetkowski, R. J., Meldrum, D. R., Steingold, K. A., Randle, D., Lu, J. K., Eggena, P., Hershman, J. M., Alkjaersig, N. K., Fletcher, A. P., & Judd, H. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142505 · Cited by 482
Biologic effects of transdermal estradiol
Chetkowski, R. J., Meldrum, D., & Ka, S. (1987) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(87)90325-0 · Cited by 467

Show all 32 references

Research works printed but not linked: 4

Feinleib M, 1968, J Natl Cancer Inst, 41, 315
Committee on the relationship Between Oral Contraceptives and Breast Cancer, Institute of Medicine. Oral contraceptives & breast cancer. Washington, D.C.: National Academy Press, 1991.
Gambrell RD, 1983, Obstet Gynecol, 62, 435
Rose DP, 1977, Obstet Gynecol, 49, 80

Sorted by citations

Items 501–600 of 999

Assessment of Breast Tissue Changes on Hormonal Replacement Therapy Using MRI: A Pilot Study
Reichenbach, J. R., Przetak, C., Klinger, G., & Kaiser, W. A. (1999) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199905000-00015 · Cited by 35
Hormone replacement therapy: assessment of present use, costs, and trends.
Townsend, J. L. (1998) · Europe PMC (PubMed Central) · Cited by 35
Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies
Verheul, H. A. M., Bennink, H. J. T. C., Kenemans, P., Atsma, W. J., Burger, C. W., Eden, J., Hammar, M. L., Marsden, J., & Purdie, D. W. (2000) · Maturitas · doi:10.1016/s0378-5122(00)00150-x · Cited by 35
Dietary fat and breast cancer.
Willett, W. C. (1999) · Toxicological Sciences · doi:10.1093/toxsci/52.suppl_1.127 · Cited by 19
Raloxifene and/or estradiol decrease anxiety-like and depressive-like behavior, whereas only estradiol increases carcinogen-induced tumorigenesis and uterine proliferation among ovariectomized rats
Walf, A. A., & Frye, C. A. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833a5cb0 · Cited by 34
“However, these types of E2-mimetic treatments can increase the risks of some women for cardiovascular complications and reproductive cancers (breast, uterine; Colditz et al., 1995; Collaborative Group on Hormonal Factors in Breast Cancer, 1997; Magnusson et al., 1999).”
Background
Multiple Pathways Involved in Palmitic Acid-Induced Toxicity: A System Biology Approach
Osorio, D., Pinzón, A. M., Martín-Jiménez, C., Barreto, G. E., & González, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01410 · Cited by 36
Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK—Results based on the Women's Health Initiative randomised controlled trial
Lekander, I., Borgström, F., Ström, O., Zethraeus, N., & Kanis, J. А. (2007) · Bone · doi:10.1016/j.bone.2007.09.059 · Cited by 34
“Enthusiasm for HT was further bolstered by information from observational studies showing lower risks of cardiovascular disease in women treated with HT, but offset by inconsistent reports that HT was associated with an increased risk of breast cancer [2,4–7].”
Result
Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: Results based on the Women's Health Initiative randomized controlled trial
Zethraeus, N., Borgström, F., Jönsson, B., & Kanis, J. А. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462305050609 · Cited by 34
“Evidence of the effect of HRT on breast cancer has been inconclusive, but now the general belief is that the risk of breast cancer increases [1, 4, 6-11].”
Background
Estrogen after ischemic stroke: Clinical basis and design of The Women's Estrogen for Stroke Trial
Kernan, W. N., Brass, L. M., Viscoli, C. M., Sarrel, P. M., Makuch, R., & Horwitz, R. I. (1998) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/s1052-3057(98)80026-8 · Cited by 34
A Partial Estrogen Receptor Agonist With Strong Antiatherogenic Properties Without Noticeable Effect on Reproductive Tissue in Cholesterol-Fed Female and Male Rabbits
Holm, P. K., Shalmi, M., Korsgaard, N., Guldhammer, B., Skouby, S. O., & Stender, S. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.10.2264 · Cited by 34
Women and coronary heart disease
Flavell, C. M. (1996) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.1996.34428 · Cited by 34
Alternatives to the Use of Estrogen in Postmenopausal Women
Pinkerton, J. V., & Santen, R. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0369 · Cited by 34
“3) of breast cancer with long-term use (116), and increased risk of venous thrombosis (117) and gallstones (118).”
Background
Postmenopausal Hormone Therapy and Breast Cancer Prognostic Characteristics: A Linkage between Nationwide Registries
Román, M., Graff‐Iversen, S., Weiderpass, E., Vangen, S., Sakshaug, S., Hofvind, S. S. H., & Ursin, G. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0240 · Cited by 33
Incidence of Breast Cancer in Younger Women: A Canadian Trend Analysis
Seely, J. M., Ellison, L. F., Billette, J., Zhang, S. X., & Wilkinson, A. N. (2024) · Canadian Association of Radiologists Journal · doi:10.1177/08465371241246422 · Cited by 33
“In 1995, Colditz reported on the increased risk of BC among postmenopausal women using HRT. 32 The Women’s Health Initiative study was stopped pre-maturely in 2002 after noting an increased risk of BC in women taking HRT. 33 Subsequent studies found that 1 out of 50 women who had taken HRT for 5 years starting at age…”
Hormone replacement therapy and breast carcinoma risk in Hispanic and non‐Hispanic women
Li, R., Gilliland, F. D., Baumgartner, K. B., & Samet, J. (2002) · Cancer · doi:10.1002/cncr.10791 · Cited by 33
Semiautomatic Mammographic Parenchymal Patterns Classification Using Multiple Statistical Features
Castella, C., Kinkel, K., Eckstein, M. P., Sottas, P., Verdun, F. R., & Bochud, F. O. (2007) · Academic Radiology · doi:10.1016/j.acra.2007.07.014 · Cited by 33
“While the etiology of breast cancer remains unclear, many studies have demonstrated a correlation between cancer risk and factors such as age, breast-feeding and pregnancy history, family history of breast cancer, hormonal treatments, genetic factors, and breast density (1-7).”
Background
Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin
Colditz, G. A. (2007) · Breast Cancer Research · doi:10.1186/bcr1736 · Cited by 33
“However, by 1995 prospective data indicated that E&P therapy did not protect against breast cancer and that the increase in risk may be greater than for estrogen alone [4].”
Cost effectiveness scenario analysis for a proposed trial of hormone replacement therapy
Townsend, J. L., & Buxton, M. J. (1997) · Health Policy · doi:10.1016/s0168-8510(96)00870-6 · Cited by 33
Effects of 17α-dihydroequilenin sulfate on atherosclerotic male and female rhesus monkeys
Washburn, S. A., Honoré, E. K., Cline, J. M., Helman, M., Wagner, J. D., Adelman, S. J., & Clarkson, T. B. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70144-8 · Cited by 33
Estrogen Therapy for Postmenopausal Symptoms and Prevention of Osteoporosis
Sagraves, R. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04141.x · Cited by 33
Hormone replacement therapy and the breast
Dixon, J. M. (2001) · BMJ · doi:10.1136/bmj.323.7326.1381 · Cited by 33
Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies
Kim, S., Ko, Y., Lee, H. J., & Lim, J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4782-2 · Cited by 32
“…10,472 (198) ET EPT Pre + Post Type of HRT use Liu (2016) Taiwan Cohort 22,929 (217) HRT ET EPT ≥ 45 Pre + Post Type of HRT use Duration of HRT use Colditz (1995) USA Cohort 69,586 (1935) ET EPT PT 30 to 55 Post Type of HRT use RCT randomized controlled trial, HRT any hormone replacement…”
Method
The Novel p38 Inhibitor, Pamapimod, Inhibits Osteoclastogenesis and Counteracts Estrogen-Dependent Bone Loss in Mice
Zhao, X., Ning, L., Xie, Z., Jie, Z., Li, X., Wan, X., Sun, X., Huang, B. H., Tang, P., Shen, S., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3655 · Cited by 31
“Longterm hormone-replacement therapy could increase the risk of vaginal bleeding, deep vein thrombosis, pulmonary embolism,((28)) breast tenderness, and even breast cancer.((29,30)) A side effect of bisphosphonates, a rare but serious osteonecrosis of the jaw, has also been reported.”
Background
Hormone replacement therapy: clinical benefits and side-effects
Lignieres, B. D. (1996) · Maturitas · doi:10.1016/s0378-5122(96)90012-2 · Cited by 32
Effect of soy isoflavone supplementation on nitric oxide metabolism and blood pressure in menopausal women
Wong, W. W., Taylor, A. A., Smith, E. O., Barnes, S., & Hachey, D. L. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.032045 · Cited by 32
Counseling Women in Midlife: An Integrative Approach to Menopause
Huffman, S. B., & Myers, J. E. (1999) · Journal of Counseling & Development · doi:10.1002/j.1556-6676.1999.tb02449.x · Cited by 32
The search for the ideal SERM
Dunn, B., Anthony, M., & Arun, B. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.6.681 · Cited by 32
“This position has evolved from the observed association between exogenous oestrogen use and breast cancer risk among healthy women [4-6].”
Background
Recent Patterns of Hormone Replacement Therapy Use in a Large Managed Care Organization
WHITLOCK, E. P., Johnson, R. E., & VOGT, T. M. (1998) · Journal of Women s Health · doi:10.1089/jwh.1998.7.1017 · Cited by 32
Progestins and their effects on the breast
Druckmann, R. A. (2003) · Maturitas · doi:10.1016/j.maturitas.2003.09.020 · Cited by 32
“Partial effects of progesterone and synthetic progestins (modified from Lober [17].”
BackgroundResultInfluential
Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights
Batra, H. V., Mouabbi, J. A., Ding, Q., Şahin, A. A., & Raso, M. G. (2023) · Cancers · doi:10.3390/cancers15225491 · Cited by 35
Progesterone promotes immunomodulation and tumor development in the murine mammary gland
Werner, L. R., Gibson, K. A., Goodman, M. L., Helm, D. E., Walter, K. R., Holloran, S. M., Trinca, G. M., Hastings, R. C., Yang, H. H., Hu, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001710 · Cited by 31
Practical measurement of total and bioavailable estradiol in female macaques
Pazol, K., Kaplan, J. R., Abbott, D. H., Appt, S. E., & Wilson, M. E. (2003) · Clinica Chimica Acta · doi:10.1016/j.cccn.2003.10.010 · Cited by 31
Intracoronary Genistein Acutely Increases Coronary Blood Flow in Anesthetized Pigs through β-Adrenergic Mediated Nitric Oxide Release and Estrogenic Receptors
Grossini, E., Molinari, C. G., Mary, D., Uberti, F., Caimmi, P. P., Surico, N., & Vacca, G. (2008) · Endocrinology · doi:10.1210/en.2007-1361 · Cited by 30
Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus
Bernatsky, S. (2004) · British journal of rheumatology · doi:10.1093/rheumatology/keh282 · Cited by 31
“Hormone replacement therapy (HRT) is increasingly recognized as a risk factor for breast cancer in the general population [8–10].”
Background
Alcohol Exposure and Breast Cancer: Results of the Women's Contraceptive and Reproductive Experiences Study
McDonald, J. A., Mandel, M. G., Marchbanks, P. A., Folger, S. G., Daling, J. R., Ursin, G., Simon, M. S., Bernstein, L., Strom, B. L., Norman, S. A., et al. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.2106.13.12 · Cited by 31
“is consistent with the importance of current and recent exposure to hormonal contraceptives (42) and hormone replacement therapy (43-48).”
Result
Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause
Takahashi, K. (2000) · Human Reproduction · doi:10.1093/humrep/15.5.1028 · Cited by 31
“…remains controversial regarding the development ofClinical parameters including Kupperman index (KI) and breast cancer (Bergkvist et al., 1989; Colditz et al., 1995).the degree of satisfaction with symptomatic relief; serum The benefits of HRT must always be weighed against their…”
Background
The Combination of a Novel Selective Estrogen Receptor Modulator with an Estrogen Protects the Mammary Gland and Uterus in a Rodent Model: The Future of Postmenopausal Women’s Health?
Labrie, F., Elalfy, M., Berger, L., Labrie, C., Martel, C., Bélanger, A., Candas, B., & Pelletier, G. (2003) · Endocrinology · doi:10.1210/en.2003-0269 · Cited by 31
Use of Oral Conjugated Estrogen Alone and Risk of Breast Cancer
Zhang, S. M., Manson, J. E., Rexrode, K. M., Cook, N. R., Buring, J. E., & Lee, I.-M. M. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwk038 · Cited by 31
“Of these, only four studies have specifically studied the use of oral conjugated estrogen alone rather than combined or unspecified categories of estrogen-alone therapy (9, 10, 21, 24).”
Background
Using Economics to Prioritize Research: A Case Study of Randomized Trials for the Prevention of Hip Fractures Due to Osteoporosis
Torgerson, D. J., Donaldson, C., & Reid, D. M. (1996) · Journal of Health Services Research & Policy · doi:10.1177/135581969600100305 · Cited by 31
Oxidative DNA Damage Following Microsome/Cu(II)-Mediated Activation of the Estrogens, 17β-Estradiol, Equilenin, and Equilin: Role of Reactive Oxygen Species
Spencer, W. A., Vadhanam, M. V., Jeyabalan, J., & Gupta, R. C. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200356v · Cited by 30
Curcumin inhibits BACE1 expression through the interaction between ERβ and NFκB signaling pathway in SH-SY5Y cells
Huang, P., Zheng, N., Zhou, H., & Huang, J. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03638-0 · Cited by 31
Diagnostic Challenge of Invasive Lobular Carcinoma of the Breast: What Is the News? Breast Magnetic Resonance Imaging and Emerging Role of Contrast-Enhanced Spectral Mammography
Costantini, M., Montella, R. A., Fadda, M. P., Tondolo, V., Franceschini, G., Bove, S., Garganese, G., & Rinaldi, P. M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060867 · Cited by 30
Post-menopausal women and osteoporosis: available choices for maintenance of skeletal health
Termine, J. D., & Wong, M. (1998) · Maturitas · doi:10.1016/s0378-5122(98)00092-9 · Cited by 30
“However, prolonged HRT usage (\5 years) is associated with an increased relative risk of developing breast cancer, compared with nonhormone use [15,20].”
Background
Involvement of internal genitalia in female patients undergoing radical cystectomy for bladder cancer: a clinicopathologic study of 37 cases
Groutz, A., GILLON, G., Konichezky, M., Shimonov, M., WINKLER, H. Z., Livne, P. M., & Baniel, J. (1999) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.1999.99039.x · Cited by 30
Breast cancer: critical data analysis concludes that estrogens are not the cause, however lifestyle changes can alter risk rapidly
Wiseman, R. A. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2003.10.017 · Cited by 30
Hip Fracture Prevention
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119050-00002 · Cited by 30
Hormone replacement therapy in the menopause: a pro opinion
Smith, H. O., KAMMERER-DOAK, D. N., Barbo, D. M., & Sarto, G. E. (1996) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.46.6.343 · Cited by 30
Prevention and Treatment of Osteoporosis: Does the Future Belong to Hormone Replacement Therapy?
Gibaldi, M. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04292.x · Cited by 30
Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study
Donovitz, G. S., & Cotten, M. (2021) · European Journal of Breast Health · doi:10.4274/ejbh.galenos.2021.6213 · Cited by 29
“Most recently, current authors have submitted for publication a 7-year study titled Low Complication Rates of T and E Implants for androgen and ET Replacement Therapy (ERT) in over one million procedures.”
BackgroundMethod
HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?
Stevenson, J. C. (2006) · Human Reproduction · doi:10.1093/humrep/del043 · Cited by 29
“This concern is not new (Colditz et al., 1995).”
Pharmacoepidemiology
Garbe, E., & Suissa, S. (2005) · Springer eBooks · doi:10.1007/978-3-540-26577-1_31 · Cited by 29
Synthesis and pharmacological evaluation of novel cis-3,4-Diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor
Bury, P. S., Christiansen, L. B., Jacobsen, P., Jørgensen, A. S., Kanstrup, A., Nærum, L., Bain, S., Fledelius, C., Gissel, B., Hansen, B. S., et al. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00257-7 · Cited by 29
Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD
Ginsburg, E. S., Walsh, B. W., Greenberg, L., Price, D., Chertow, G. M., & Owen, W. F. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00087.x · Cited by 29
“These potential benefits must be balanced against the possible increased risks of breast cancer [62, 63], non-fatal venous thromboembolism [64], and cholelithiasis [65].”
Background
Phytoestrogen α-Zearalanol Inhibits Atherogenesis and Improves Lipid Profile in Ovariectomized Cholesterol-Fed Rabbits
Dai, S., Duan, J., Lu, Y., Zhang, Y., Cheng, J., Ren, J. T., Zhao, X., Wu, Y., Yu, Y., Zuo, P., et al. (2004) · Endocrine · doi:10.1385/endo:25:2:121 · Cited by 29
Estrogen Receptor α Enhances the Rate of Oxidative DNA Damage by Targeting an Equine Estrogen Catechol Metabolite to the Nucleus
Wang, Z., Wijewickrama, G. T., Peng, K.-W., Dietz, B. M., Yuan, L., van Breemen, R. B., Bolton, J. L., & Thatcher, G. R. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807860200 · Cited by 29
Translesion Synthesis Past Equine Estrogen-Derived 2‘-Deoxyadenosine DNA Adducts by Human DNA Polymerases η and κ
Yasui, M., Laxmi, Y. R. S., Ananthoju, S. R., Suzuki, N., Kim, S. Y., & Shibutani, S. (2006) · Biochemistry · doi:10.1021/bi0525324 · Cited by 29
“However, HRT increases significantly the risk of developing breast (3), ovarian (4) and endometrial cancers (5); the longer duration of HRT showed the higher cancer risks (4,6).”
Analysis of estrogenic compounds in Polygonum cuspidatum by bioassay and high performance liquid chromatography
Zhang, C., Zhang, X., Zhang, Y., Xu, Q. N., Xiao, H., & Liang, X. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2005.10.029 · Cited by 29
The Effect of Raloxifene on Glyco-Insulinemic Homeostasis in Healthy Postmenopausal Women: A Randomized Placebo-Controlled Study
Cucinelli, F., Soranna, L., Romualdi, D., Muzj, G., Mancuso, S., & Lanzone, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011302 · Cited by 29
Megatrials of Hormonal Replacement Therapy
Wren, B. G. (1998) · Drugs & Aging · doi:10.2165/00002512-199812050-00001 · Cited by 29
Hormone Therapy and Young-Onset Breast Cancer
O’Brien, K. M., Fei, C., Sandler, D. P., Nichols, H. B., DeRoo, L. A., & Weinberg, C. R. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwu347 · Cited by 28
“Few studies have examined progestin alone (P-HT), but some have suggested an increased risk (11, 15, 18, 24).”
The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits – an attempt to interpret the Women's Health Initiative results
Kühl, H., & Stevenson, J. C. (2006) · Gynecological Endocrinology · doi:10.1080/09513590600717368 · Cited by 28
“In the Nurses’ Health Study, a reduced incidence of breast cancer was observed during the first 5 years after discontinuation of hormone therapy [44].”
Background
HRT Opposed to Low-Dose Tamoxifen (HOT Study): Rationale and Design
DeCensi, A., Galli, A., & Veronesi, U. (2003) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-55647-0_10 · Cited by 27
Base Selectivity and Effects of Sequence and DNA Secondary Structure on the Formation of Covalent Adducts Derived from the Equine Estrogen Metabolite 4-Hydroxyequilenin
Kolbanovskiy, A., Kuzmin, V. A., Shastry, A., Kolbanovskaya, M., Chen, D., Chang, M., Bolton, J. L., & Geacintov, N. E. (2005) · Chemical Research in Toxicology · doi:10.1021/tx050190x · Cited by 28
Selective estrogen receptor modulators: A new category of therapeutic agents for extending the health of postmenopausal women
Goldstein, S. R. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)70012-2 · Cited by 28
Organochlorines and Breast Cancer
Iacovo, R. D., Celentano, E., Strollo, A. M., Iazzetta, G., Capasso, I., & G, R. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-3230-6_6 · Cited by 28
Cancer risk in women receiving estrogen-progestin replacement therapy
Persson, I. (1996) · Maturitas · doi:10.1016/0378-5122(96)01010-9 · Cited by 28
Safety surveillance of esterified estrogens—methyltestosterone (Estratest® and Estratest® HS) replacement therapy in the United States
Phillips, E., & Bauman, C. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80060-4 · Cited by 28
Controversies Surrounding Estrogen Use in Postmenopausal Women
Witt, D. M., & Lousberg, T. R. (1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100615 · Cited by 28
The protective role of G protein-coupled estrogen receptor 1 (GPER-1) on methotrexate-induced nephrotoxicity in human renal epithelium cells
Kurt, A. H., Bozkuş, F., Üremiş, N., & Üremi̇ş, M. M. (2016) · Renal Failure · doi:10.3109/0886022x.2016.1155398 · Cited by 27
“Estrogen alone, estrogen plus progestin and progestins alone all appear to raise the risk of breast cancer.(33) The effects of estradiol on several more recently recognized risk markers for cardiovascular disease have been reviewed.”
Background
Antidiabetic, anthelmintic and antioxidation properties of novel and new phytocompounds isolated from the methanolic stem-bark of Vernonia amygdalina Delile (Asteraceae)
Ejiofor, I. I., Das, A., & Zaman, M. K. (2020) · Scientific African · doi:10.1016/j.sciaf.2020.e00578 · Cited by 27
Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study
Cicinelli, E., de Ziegler, D., Alfonso, R., Nicoletti, R., Bellavia, M., & Colafiglio, G. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.01.095 · Cited by 27
Hormone replacement therapy (HRT), breast cancer and tumor pathology
Dietel, M. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.11.005 · Cited by 27
Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest® 50 or Systen® (Evorel®) 50
Reginster, J., Albert, A., Deroisy, R., Colette, J., Vrijens, B., Blacker, C., Brion, N., Caulin, F., Mayolle, C., Regnard, A., et al. (1997) · Maturitas · doi:10.1016/s0378-5122(97)00027-3 · Cited by 27
Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits.
Marshall, K. G. (1996) · Europe PMC (PubMed Central) · Cited by 26
Migraine, Menopause and Hormonal Replacement Therapy
Silberstein, S. D., & Lignieres, B. D. (2000) · Cephalalgia · doi:10.1046/j.1468-2982.2000.00044.x · Cited by 27
HRT and breast cancer: Impact on population risk and incidence
Coombs, N. J., Taylor, R. J., Wilcken, N. R. C., & Boyages, J. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.030 · Cited by 27
“cancer [1–9].”
Postmenopausal hormone therapy and the risk of breast cancer in Norway
Román, M., Sakshaug, S., Graff‐Iversen, S., Vangen, S., Weiderpass, E., Ursin, G., & Hofvind, S. S. H. (2015) · International Journal of Cancer · doi:10.1002/ijc.29810 · Cited by 26
Results of Observational Studies: Analysis of Findings from the Nurses’ Health Study
Tai, V., Grey, A. B., & Bolland, M. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110403 · Cited by 28
“70) O: Breast cancer Colditz 1995 [38] Cohort study 1.”
Background
Discovery of Indeno[1,2-c]quinoline Derivatives as Inhibitors of Osteoclastogenesis Induced by Receptor Activator of NF-κB Ligand (RANKL)
Tseng, C.-H., Lin, R., Chen, Y., Wang, G., Ho, M., & Tzeng, C. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1016494 · Cited by 26
The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions
Temkin, S. M., Mallen, A. R., Bellavance, E. C., Rubinsak, L. A., & Wenham, R. M. (2018) · Cancer · doi:10.1002/cncr.31911 · Cited by 26
“0).(63) The Collaborative Group for Hormonal Risk Factors in Breast Cancer subsequently conducted a comprehensive, international metaanalysis of individual data on 17,949 postmenopausal women with breast cancer and 35,916 controls, concluding that combined MHT is associated with breast cancer risk similar to that of l…”
Background
Osteoporosis: part II. Nonpharmacologic and pharmacologic treatment.
South-Paul, J. E. (2001) · PubMed · Cited by 26
Postmenopausal hormone therapy and the risk of breast cancer
Speroff, L. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31812f7b55 · Cited by 26
Endocrine and lipid effects of oral L -arginine treatment in healthy postmenopausal women
Blum, A., Cannon, R. O., Costello, R., Schenke, W. H., & Csákó, G. (2000) · Journal of Laboratory and Clinical Medicine · doi:10.1067/mlc.2000.104909 · Cited by 26
Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells
Kato, S., Pinto, M. P., Carvajal, A., Espinoza, N., Monso, C., Bravo, L., Villalón, M., Cuello, M. A., Quest, A. F. G., Suenaga, A., et al. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-01-0066 · Cited by 26
Primary and secondary malignant involvement of gynaecological organs at radical cystectomy for bladder cancer: Review of literature and retrospective analysis of 360 cases
Salem, H. K., & El-Mazny, A. N. (2012) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2012.693980 · Cited by 26
“Prolonged hormone replacement therapy used to alleviate symptoms and minimise these risks has been associated with increased incidence of breast cancer, especially if used for more than 5 years (Colditz et al. 1995).”
Background
Depressive, Not Anxiety, Symptoms Are Associated With Current Cigarette Smoking Among University Internal Medical Patients
Kick, S. D., & Cooley, D. D. (1997) · Psychosomatics · doi:10.1016/s0033-3182(97)71482-8 · Cited by 26
Evaluation of the Estrogenic Activity of Leguminosae Plants
Yoo, H. H., Kim, T., Ahn, S., Kim, Y. J., Kim, H., Piao, X. L., & Park, J. H. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.538 · Cited by 26
Management of osteoporosis in patients with gastrointestinal diseases
von Tirpitz, C., & Reinshagen, M. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200308000-00006 · Cited by 26
Tissue Distribution and Pharmacological Potential of SM-16896, a Novel Oestrogen-bisphosphonate Hybrid Compound
Tsushima, N., Yabuki, M., Harada, H., Katsumata, T., Kanamaru, H., Nakatsuka, I., Yamamoto, M., & Nakatsuka, M. (2000) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357001773652 · Cited by 26
“…drugs for postmenopausal osteoporosis (Lindsay 1993; Lobo 1995; Maxim et al 1995), but because of their possible side effects such as increased risk of cancer (Bergkvist et al 1989; Cummings 1991; Colditz et al 1995), oestrogens which exert their oestrogenic effects selectively on bone are desired.”
Background
Why do women doctors in the UK take hormone replacement therapy?
Isaacs, A., Britton, A. R., & McPherson, K. (1997) · Journal of Epidemiology & Community Health · doi:10.1136/jech.51.4.373 · Cited by 26
Hormone replacement therapy and breast cancer.
Jacobs, H. S. (2000) · Endocrine Related Cancer · doi:10.1677/erc.0.0070053 · Cited by 26
“The results from the Nurses’ Health Study indicated that, with respect to breast cancer, gestogens conferred no protection from the risk of treatment with oestrogen (Colditz et al. 1995).”
Result
Exogenous reproductive hormone use in breast cancer survivors and previvors
Vaz-Luís, I., & Partridge, A. H. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.207 · Cited by 25
Identification of new triarylethylene oxyalkanoic acid analogues as bone selective estrogen mimetics
Rubin, V. N., Ruenitz, P. C., Boudinot, F. D., & Boyd, J. L. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00038-4 · Cited by 25
Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study
Chen, W., Petitti, D. B., & Geiger, A. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602701 · Cited by 25
“In 1995, the Nurses’ Health Study reported a relative risk of death from breast cancer of 1.14 (95% CI 0.85–1.51) for current hormone users and a risk of 1.45 (95% CI 1.01– 2.09) for hormone users of five or more years (Colditz et al, 1995).”
BackgroundInfluential
Oxidative DNA Damage in XPC-Knockout and Its Wild Mice Treated with Equine Estrogen
Okamoto, Y., Chou, P., Kim, S. Y., Suzuki, N., Laxmi, Y. R. S., Okamoto, K., Liu, X., Matsuda, T., & Shibutani, S. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700428m · Cited by 26
Postmenopausal hormone replacement therapy and cancer of the female genital tract and breast
Burger, C. W., & Kenemans, P. (1998) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-199802000-00008 · Cited by 25
Estrogen Replacement
Sullivan, J. M. (1996) · Circulation · doi:10.1161/01.cir.94.11.2699 · Cited by 25
Evaluation of Contextual and Demographic Factors on Licorice Effects on Reducing Hot Flashes in Postmenopause Women
menati, L., Khaleghinezhad, K., Tadayon, M., & Siahpoosh, A. (2013) · Health Care For Women International · doi:10.1080/07399332.2013.770001 · Cited by 24
“Thromboembolic events decreased the tendency of women to continue HRT (Colditz et al., 1995; Mørch, Løkkegaard, Andreasen, Kjær, & Lidegaard, 2012, Pretorius, Oberholzer, van der Spuy, & Meiring, 2010; Reeves, Beral, Green, Gathani, & Bull, 2006).”
Differential effects of estrogen and progesterone on potassium channels expressed in Xenopus oocytes
Wong, C., Tsang, S. Y., Yao, X., Chan, F. L., & Huang, Y. (2008) · Steroids · doi:10.1016/j.steroids.2007.10.010 · Cited by 24
Differential effects of 17β-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency
Naves‐Díaz, M., Carrillo‐López, N., Rodríguez-Rodríguez, A., Braga, S., Fernández‐Coto, T., López-Novoa, J. M., López-Hernández, F. J., & Cannata-Andía, J. B. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181ce6874 · Cited by 24
“Although progestogens have been added to diminish this problem, estrogen plus progestogen has showed a significantly increased risk of breast cancer.(5) These findings, together with the absence of a protective effect on the cardiovascular and other systems, have significantly reduced the use of estrogen.”
Background

Authors: Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Colditz, Graham A.
Hankinson, Susan E.
Willett, Walter C.
Manson, JoAnn E.
Stampfer, Meir J.
Hennekens, Charles
Rosner, Bernard
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-06-15
Volume: 332
Issue: 24
Pages: 1589-1593
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199506153322401
OpenAlex: W2607238143
Cited by: 1,487
References: 32
Citations by year: 2026: 5 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 13 · 2020: 13 · 2019: 11 · 2018: 17 · 2017: 16 · 2016: 16 · 2015: 18 · 2014: 21 · 2013: 18 · 2012: 26
FWCI: 111.38
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA 40956)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords: breast cancer risk, hormone replacement therapy, estrogen therapy, progestins, estrogen plus progestin, duration of hormone use, age-related risk, breast cancer mortality, Nurses' Health Study
MeSH terms: Aged, Breast Neoplasms, Estrogens, Female, Follow-Up Studies, Humans, Middle Aged, Progestins, Prospective Studies, Risk, Risk Factors, Cohort Studies, Estrogen Replacement Therapy, Confidence Intervals, Case-Control Studies, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks